Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 31, 2006
Event: Entry into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Specific metrics include:
- Shares Issued: 5,115,961 shares of Common Stock.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 767,394 additional shares.
- Offering Price: $13.00 per share.
- Expected Net Proceeds: Approximately $62.3 million (net of underwriting discounts, commissions, and estimated offering expenses).
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the underwriting agreement dated January 31, 2006. The offering was registered under Form S-3 (File No. 333-129905 and 333-131233).
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the offering with Morgan Stanley & Co. Incorporated, Banc of America Securities LLC, Piper Jaffray & Co., SG Cowen & Co., LLC, and Rodman & Renshaw, LLC as underwriters.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard terms of the underwriting agreement and the potential exercise of the over-allotment option.
Investor Verification Checklist
- Verify the final number of shares sold if the over-allotment option is exercised within the 30-day period.
- Confirm the actual net proceeds received after final settlement of underwriting fees and expenses.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific covenants or restrictions.
- Check subsequent filings for the use of proceeds and impact on diluted earnings per share.